Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic / 전남의대학술지
Chonnam Medical Journal
;
: 1-7, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-788307
ABSTRACT
Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma (MM) is still difficult to cure. Alternative approaches are clearly needed to prolong the survival of patients with MM. Dendritic cell (DC) therapy is a very promising tool immunologically in MM. We developed a method to generate potent DCs with increased Th1 polarization and migration ability for inducing strong myeloma-specific cytotoxic T lymphocytes. In this review, we discuss how the efficacy of cancer immunotherapy using DCs can be improved in MM.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Células Dendríticas
/
Linfocitos T Citotóxicos
/
Trasplante de Células Madre
/
Inmunoterapia
/
Mieloma Múltiple
Límite:
Humanos
Idioma:
Inglés
Revista:
Chonnam Medical Journal
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS